Ann Lab Med.  2017 Mar;37(2):177-179. 10.3343/alm.2017.37.2.177.

Concomitant AID Expression and BCL7A Loss Associates With Accelerated Phase Progression and Imatinib Resistance in Chronic Myeloid Leukemia

Affiliations
  • 1Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea. KAL1119@yuhs.ac
  • 2Department of Laboratory Medicine, Hallym University College of Medicine, Kangnam Sacred Heart Hospital, Seoul, Korea.
  • 3Department of Laboratory Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.

Abstract

No abstract available.


MeSH Terms

Aged
Cytidine Deaminase/*genetics/metabolism
Dasatinib/therapeutic use
Disease Progression
Drug Resistance, Neoplasm
Fusion Proteins, bcr-abl/genetics/metabolism
Humans
Imatinib Mesylate/*therapeutic use
In Situ Hybridization, Fluorescence
Karyotype
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy
Male
Microfilament Proteins/*genetics/metabolism
Oncogene Proteins/*genetics/metabolism
Protein Kinase Inhibitors/*therapeutic use
Cytidine Deaminase
Dasatinib
Fusion Proteins, bcr-abl
Imatinib Mesylate
Microfilament Proteins
Oncogene Proteins
Protein Kinase Inhibitors
Full Text Links
  • ALM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr